<DOC>
	<DOCNO>NCT02152709</DOCNO>
	<brief_summary>The main objective study evaluate safety immunogenicity 10µg/0.5ml 5µg/0.5ml hepatitis B vaccine make recombinant deoxyribonudeic acid technique saccharomyces cereviside yeast infant age group .</brief_summary>
	<brief_title>Study Evaluating Safety Immunogenicity 10µg/0.5ml Hepatitis B Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria ( For Infant Group ) : Healthy fullterm infant birth , Apgar score ≥7 . Guardian sign informed consent . Guardian comply requirement clinical trial . Without administer immunoglobulin follow period . Axillary temperature ≤37.0 ℃ . Inclusion Criteria ( For Other Age Groups ) : More 1 month old healthy people , without history hepatitis B infection . Subjects guardian sign informed consent . After question medical history , physical examination judge healthy subject . Without history hepatitis B vaccination . Subjects guardians comply requirement clinical trail . Without prevention drug immunoglobulin administer within two week clinical trail follow period . Axillary temperature ≤37.0 ℃ . Exclusion Criteria ( For Infant Group ) : Apgar score infant birth &lt; 7 . With nervous system damage birth , family history mental illness , epilepsy encephalopathy . With immune system dysfunction . With vitamin deficiency . With acute febrile disease , infectious disease . With congenital malformation , developmental disorder serious chronic illness . With thrombocytopenia coagulation disorder . Administered immunoglobulin period clinical trail , especially administer Hepatitis B immunoglobulin infant Hepatitis B infect mother . With endemic disease . Participate another clinical trial period clinical trail . Any circumstance may affect clinical trail evaluation . Exclusion Criteria ( For Other Age Groups ) : With allergy , seizure , epilepsy , encephalopathy family history mental illness . Allergic component study vaccine . With immune system dysfunction . Hepatitis B infected people . AntiHBs positive screen ELISA kit . Either antiHBs ≥10mIU/ml HBsAg positive screen Radioimmunoassay method . With acute febrile diseases infectious disease . With congenital malformation , developmental disorder serious chronic illness . With thrombocytopenia coagulation disorder . With history severe allergic reaction . Administered prevention drug immunoglobulin within two week clinical trail follow period . With acute illness require antibiotic antiviral treatment within 7 day clinical trail . With vitamin deficiency . With history febrile convulsion . Axillary temperature ≥38.0 ℃ within 3 day clinical trail . Participate another clinical trial period clinical trail . Pregnant woman . Any circumstance may affect clinical trail evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>